News | November 13, 2023
Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr
US business grew by +12.8% YoY
US business grew by +12.8% YoY
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Study efficacy measures will include the expression of dystrophin protein and motor function.
Marksans' OTC Famotidine Tablets USP are acid reducers
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
